Learn More
A critical challenge facing the advocates of biotechnology is to fortify the biosafety of genetically engineered organisms. Readers of this journal have seen competing notions on how to achieve biosafety. For some, scientists carry the burden of designing better biosafety through 'backup safety precau-tions' 1 and 'molecular gene-containment strategies' 2.(More)
We agree with the thesis of Rosen et al. [1] that, despite initiatives such as the World Health Organization's " 3 by 5 " program, rationing of HIV/AIDS antiretroviral therapy (ART) will be necessary in the majority of African countries. Diffi cult choices will need to be made, and choices will be constrained due to the limited health infrastructure and(More)
  • R L Krall
  • 2011
We undertook a survey of the current capability in the United States to conduct controlled clinical trials. The intention was to use the results as a foundation for understanding how to create a controlled clinical trial capability sufficient to meet future needs of US health care. For this purpose, using the results from an advanced search of(More)